EA036434B1 - Способ лечения рака легких с применением комбинации ингибитора киназы аврора и паклитаксела - Google Patents

Способ лечения рака легких с применением комбинации ингибитора киназы аврора и паклитаксела Download PDF

Info

Publication number
EA036434B1
EA036434B1 EA201491727A EA201491727A EA036434B1 EA 036434 B1 EA036434 B1 EA 036434B1 EA 201491727 A EA201491727 A EA 201491727A EA 201491727 A EA201491727 A EA 201491727A EA 036434 B1 EA036434 B1 EA 036434B1
Authority
EA
Eurasian Patent Office
Prior art keywords
aurora
cancer
paclitaxel
dose
kinase inhibitor
Prior art date
Application number
EA201491727A
Other languages
English (en)
Russian (ru)
Other versions
EA201491727A1 (ru
Inventor
Ариджит Чакраварти
Джеффри А. Эксиди
Роберт В. Клейнфилд
Кха Н. Ли
Вен Чуи Шю
Картхик Венкатакришнан
Original Assignee
Милленниум Фармасьютикалз, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Милленниум Фармасьютикалз, Инк. filed Critical Милленниум Фармасьютикалз, Инк.
Publication of EA201491727A1 publication Critical patent/EA201491727A1/ru
Publication of EA036434B1 publication Critical patent/EA036434B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
EA201491727A 2012-03-20 2013-03-19 Способ лечения рака легких с применением комбинации ингибитора киназы аврора и паклитаксела EA036434B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261613258P 2012-03-20 2012-03-20
PCT/US2013/032962 WO2013142491A1 (en) 2012-03-20 2013-03-19 Methods of treating cancer using aurora kinase inhibitors

Publications (2)

Publication Number Publication Date
EA201491727A1 EA201491727A1 (ru) 2015-01-30
EA036434B1 true EA036434B1 (ru) 2020-11-10

Family

ID=48048255

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201491727A EA036434B1 (ru) 2012-03-20 2013-03-19 Способ лечения рака легких с применением комбинации ингибитора киназы аврора и паклитаксела

Country Status (24)

Country Link
US (2) US20130303519A1 (enExample)
EP (1) EP2827855B1 (enExample)
JP (1) JP6373252B2 (enExample)
KR (1) KR102128866B1 (enExample)
CN (1) CN104271129A (enExample)
AU (1) AU2013235275B2 (enExample)
CA (1) CA2868024A1 (enExample)
EA (1) EA036434B1 (enExample)
ES (1) ES2746946T3 (enExample)
GE (2) GEP20186900B (enExample)
IL (1) IL234686B (enExample)
IN (1) IN2014DN08477A (enExample)
JO (1) JO3630B1 (enExample)
MA (1) MA37438A1 (enExample)
MX (1) MX358411B (enExample)
MY (1) MY175225A (enExample)
NZ (1) NZ700744A (enExample)
PH (1) PH12014502109A1 (enExample)
SG (2) SG10201607741RA (enExample)
TN (1) TN2014000387A1 (enExample)
TW (1) TWI649082B (enExample)
UA (1) UA117455C2 (enExample)
WO (1) WO2013142491A1 (enExample)
ZA (1) ZA201407551B (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130303519A1 (en) 2012-03-20 2013-11-14 Millennium Pharmaceuticals, Inc. Methods of treating cancer using aurora kinase inhibitors
CA2972076A1 (en) * 2014-12-23 2016-06-30 Millennium Pharmaceuticals, Inc. Combination of raf inhibitors and aurora kinase inhibitors
JP6786530B2 (ja) * 2015-07-02 2020-11-18 ミレニアム ファーマシューティカルズ， インコーポレイテッドＭｉｌｌｅｎｎｉｕｍ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． オーロラａキナーゼの選択的インヒビターに対する応答のバイオマーカー
CN114681455A (zh) * 2018-08-17 2022-07-01 深圳微芯生物科技股份有限公司 组蛋白去乙酰化酶抑制剂与蛋白激酶抑制剂之组合及其制药用途

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008063525A1 (en) * 2006-11-16 2008-05-29 Millennium Pharmaceuticals, Inc. Compounds for inhibiting mitotic progression

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4099012A (en) 1975-08-28 1978-07-04 Ciba-Geigy Corporation 2-pyrazolyl-benzophenones
US4481142A (en) 1979-02-07 1984-11-06 Hoffmann-La Roche Inc. Pyrimido-2-benzazepines
NZ192803A (en) 1979-02-07 1984-08-24 Hoffmann La Roche Pyrimido-2-benzazepines and pharmaceutical compositions
US4469633A (en) 1980-05-16 1984-09-04 Hoffmann-La Roche Inc. N-oxides of 5-oxo-1-phenyl-2-benzazepines
EP0273697A3 (en) 1986-12-30 1989-11-29 Merck & Co. Inc. 2-benzazepines with 5- and 6- membered heterocyclic rings
US5166151A (en) 1988-03-25 1992-11-24 Merck & Co., Inc. 2-Benzazepines with 5- and 6-membered heterocyclic rings, compositions and medical methods of use thereof
US5210082A (en) 1991-05-16 1993-05-11 Merck & Co., Inc. 2-benzazepines with 5- and 6-membered heterocyclic rings to treat pain and anxiety disorders
US6096331A (en) 1993-02-22 2000-08-01 Vivorx Pharmaceuticals, Inc. Methods and compositions useful for administration of chemotherapeutic agents
US5747487A (en) 1993-07-29 1998-05-05 American Cyanamid Company Tricyclic benzazepine vasopressin antagonists
GB9523675D0 (en) 1995-11-20 1996-01-24 Celltech Therapeutics Ltd Chemical compounds
EP0888350A1 (en) 1996-03-08 1999-01-07 Zeneca Limited Azolobenzazepine derivatives as neurologically active agents
EP0946523A1 (en) 1996-12-23 1999-10-06 Celltech Therapeutics Limited Fused polycyclic 2-aminopyrimidine derivatives, their preparation and their use as protein tyrosine kinase inhibitors
GB9713087D0 (en) 1997-06-20 1997-08-27 Celltech Therapeutics Ltd Chemical compounds
ES2191963T3 (es) 1997-09-29 2003-09-16 Meiji Seika Kaisha Derivados triciclicos de triazolobenzazepina, proceso para la obtencion de los mismos y agentes antialergicos.
US6277844B1 (en) 1998-09-14 2001-08-21 Sydney Spector Compound for selective treatment of malignant cells by inhibiting cell cycle progression, decreasing Bcl2, and increasing apoptosis
US6417207B1 (en) 1999-05-12 2002-07-09 Nitromed, Inc. Nitrosated and nitrosylated potassium channel activators, compositions and methods of use
WO2002022605A1 (en) 2000-09-15 2002-03-21 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
US6989385B2 (en) 2000-12-21 2006-01-24 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
SI20848A (sl) 2001-03-14 2002-10-31 Lek, Tovarna Farmacevtskih In Kemijskih Izdelkov, D.D. Farmacevtska formulacija, ki vsebuje atorvastatin kalcij
US6686352B2 (en) 2001-05-18 2004-02-03 Hoffmann-La Roche Inc. Substituted imidazo [1,5-a] pyrimido [5,4-d] [1] benzazepine derivatives
DE10135457A1 (de) 2001-07-20 2003-02-06 Adc Automotive Dist Control Optische Sensoranordnung
JP4364637B2 (ja) 2001-08-09 2009-11-18 アクテリオン ファーマシューティカルズ リミテッド 新規なベンゾ縮合へテロ環化合物
CN1897950A (zh) 2003-10-14 2007-01-17 惠氏公司 稠合芳基和杂芳基衍生物及其使用方法
WO2005076987A2 (en) 2004-02-10 2005-08-25 Santarus, Inc. Combination of proton pump inhibitor, buffering agent, and nonsteroidal anti-inflammatory agent
AU2005243175B2 (en) 2004-05-14 2011-12-01 Millennium Pharmaceuticals, Inc. Compounds and methods for inhibiting mitotic progression by inhibition of Aurora kinase
CN101084214A (zh) 2004-11-17 2007-12-05 迈卡纳治疗股份有限公司 激酶抑制剂
WO2006070198A1 (en) 2004-12-30 2006-07-06 Astex Therapeutics Limited Pyrazole derivatives as that modulate the activity of cdk, gsk and aurora kinases
EA200870117A1 (ru) 2005-12-23 2008-12-30 Смитклайн Бичам Корпорейшн Азаиндоловые ингибиторы аурора-киназ
JP2009523784A (ja) 2006-01-16 2009-06-25 ジュビラント・オルガノシス・リミテッド 酸不安定化合物の安定な医薬製剤およびその製造方法
TW200744583A (en) 2006-03-14 2007-12-16 Ranbaxy Lab Ltd Statin stabilizing dosage formulations
DE102006012301A1 (de) 2006-03-15 2007-09-20 Cemag-Anlagenbau-Dessau Gmbh Herstellung von Zementklinker
US7718648B2 (en) 2006-08-09 2010-05-18 Millennium Pharmaceuticals, Inc. Pyridobenzazepine compounds and methods for inhibiting mitotic progression
AU2007314282A1 (en) 2006-10-31 2008-05-08 Achillion Pharmaceuticals, Inc. Elvucitabine pharmaceutical compositions
AR065802A1 (es) 2007-03-22 2009-07-01 Schering Corp Formulaciones de comprimidos que contienen sales de 8- [( 1- ( 3,5- bis- (trifluorometil) fenil) -etoxi ) - metil) -8- fenil -1, 7- diaza- spiro [ 4,5] decan -2- ona y comprimidos elaborados a partir de estas
US20090203671A1 (en) 2007-11-27 2009-08-13 Abbott Laboratories Method of treating cancer
WO2009114703A2 (en) * 2008-03-12 2009-09-17 Fox Chase Cancer Center Combination therapy for the treatment of cancer
KR101848095B1 (ko) 2008-06-26 2018-04-11 안테리오스, 인코퍼레이티드 경피 운반
JO3635B1 (ar) 2009-05-18 2020-08-27 Millennium Pharm Inc مركبات صيدلانية صلبة وطرق لانتاجها
JO3434B1 (ar) 2009-07-31 2019-10-20 Millennium Pharm Inc مركبات صيدلانية لمعالجة السرطان وامراض واضطرابات اخري
BR112012020557A8 (pt) * 2010-02-19 2018-01-02 Millennium Pharm Inc formas cristalinas de 4-{[9-cloro-7-(2-flúor-6-metoifenil)-5h-pirimido[5,4-d][2]benzazepin-2-il]amino}-2-metoxibenzoato de sódio
US20130303519A1 (en) 2012-03-20 2013-11-14 Millennium Pharmaceuticals, Inc. Methods of treating cancer using aurora kinase inhibitors

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008063525A1 (en) * 2006-11-16 2008-05-29 Millennium Pharmaceuticals, Inc. Compounds for inhibiting mitotic progression

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
"A Phase 1 Dose Escalation Study of MLN8237, an Aurora A Kinase Inhibitor, in Adult Patients With Nonhematological Malignancies, Followed by a Phase 2 of MLN8237 in Lung, Breast, Head and Neck, or Gastroesophageal Malignancies", INTERNET 30 January 2012 (2012-01-30), XP002697815, Retrieved from the Internet:URL:http://clinicaltrials.gov/archive/NCTO1045421/2012_01_30 [retrieved on 2013-05-28] the whole document *
"Randomized Phase 2 Study of MLN8237, an Aurora A Kinase Inhibitor, Plus Weekly Paclitaxel or Weekly Paclitaxel Alone in Patients With Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer, Preceded by a Phase 1 Portion in Patients With Ovarian or Breast Cancer", INTERNET 6 December 2011 (2011-12-06), XP002697811, Retrieved from the Internet:URL:http://clinicaltrials.gov/archive/NCTO1091428/2011_12_06 [retrieved on 2013-05-28] the whole document *
KELLY KEVIN R; PADMANABHAN SWAMINATHAN; GOY ANDRE; BERDEJA JESUS G; REEDER CRAIG B; MCDONAGH KEVIN T; ZHOU XIAOFEI; DANAEE HADI; X: "Results From a Phase 1 Multicenter Trial of Alisertib (MLN8237)-An Investigational Aurora A Kinase Inhibitor-in Patients with Advanced Hematologic Malignancies", BLOOD, THE AMERICAN SOCIETY OF HEMATOLOGY, US, vol. 118, no. 21, 2477, 18 November 2011 (2011-11-18) - 13 December 2011 (2011-12-13), US, pages 1061 - 1062, XP008162415, ISSN: 0006-4971 *
KOVAR HEINRICH: "AURKA Inhibitors: Right in Time", PEDIATRIC BLOOD AND CANCER, WILEY, HOBOKEN, NJ, US, vol. 55, no. 1, 15 July 2010 (2010-07-15), US, pages 3 - 4, XP002697812, ISSN: 1545-5009, DOI: 10.1002/PBC.22548 *
TSO-FU WANG, SUNG-CHAO CHU, RUEY-HO KAO, CHAO-YUAN YAO, AND CHI-CHENG LI: "A phase II study of weekly paclitaxel and epirubicin in recurrent or refractory squamous cell carcinoma of the head and neck", JAPANESE JOURNAL OF CLINICAL ONCOLOGY., TOKYO., JP, vol. 38, no. 7, 1 July 2008 (2008-07-01), JP, pages 459 - 463, XP002697813, ISSN: 0368-2811, DOI: 10.1093/JJCO/HYN052 *
YAMAMOTO NOBUYUKI, ET AL: "Phase II study of weekly paclitaxel for relapsed and refractory small cell lung cancer", ANTICANCER RESEARCH, INTERNATIONAL INSTITUTE OF ANTICANCER RESEARCH, GR, vol. 26, no. 1B, 1 January 2006 (2006-01-01), GR, pages 777 - 781, XP002697814, ISSN: 0250-7005 *

Also Published As

Publication number Publication date
TN2014000387A1 (en) 2015-12-21
US10213436B2 (en) 2019-02-26
UA117455C2 (uk) 2018-08-10
CN104271129A (zh) 2015-01-07
MX2014011324A (es) 2014-12-05
HK1206253A1 (en) 2016-01-08
CA2868024A1 (en) 2013-09-26
IL234686A0 (en) 2014-11-30
JP2015510945A (ja) 2015-04-13
PH12014502109A1 (en) 2014-12-10
US20160193224A1 (en) 2016-07-07
US20130303519A1 (en) 2013-11-14
IL234686B (en) 2020-01-30
TW201343169A (zh) 2013-11-01
GEAP201813599A (en) 2018-06-25
MY175225A (en) 2020-06-16
AU2013235275A1 (en) 2014-10-23
NZ700744A (en) 2016-09-30
ZA201407551B (en) 2019-01-30
KR20140144215A (ko) 2014-12-18
JO3630B1 (ar) 2020-08-27
MA37438A1 (fr) 2016-05-31
ES2746946T3 (es) 2020-03-09
IN2014DN08477A (enExample) 2015-05-08
EA201491727A1 (ru) 2015-01-30
WO2013142491A1 (en) 2013-09-26
GEP20186900B (en) 2018-10-10
JP6373252B2 (ja) 2018-08-15
KR102128866B1 (ko) 2020-07-01
AU2013235275B2 (en) 2017-12-07
SG11201405621UA (en) 2014-10-30
SG10201607741RA (en) 2016-11-29
TWI649082B (zh) 2019-02-01
EP2827855A1 (en) 2015-01-28
MX358411B (es) 2018-08-20
EP2827855B1 (en) 2019-06-26

Similar Documents

Publication Publication Date Title
JP6263468B2 (ja) Ｍｅｋ阻害剤およびオーロラａキナーゼの選択的阻害剤の組み合わせ
US20210100813A1 (en) Combination therapy for cancer using bromodomain and extra-terminal (bet) protein inhibitors
RU2316326C2 (ru) Способ и композиция для лечения ракового заболевания, тозилат и фармацевтически приемлемые соли n-(4-хлор-3-(трифторметил)фенил)-n'-(4-(2-(n-метилкарбамоил)-4-пиридилокси)фенил)мочевины
US11826363B2 (en) Therapeutic agent for solid cancers, which comprises Axl inhibitor as active ingredient
CN101641117B (zh) 药物组合物
IL262323A (en) Combinations for the treatment of tumors by targeting silent cell and egfr inhibitors
EP3858836A1 (en) Compound and use thereof
CN106963769A (zh) 含pi3k抑制剂和perk抑制剂的药物组合物及其应用
US10213436B2 (en) Methods of treating cancer using aurora kinase inhibitors
CA2782146A1 (en) Small pyrimidine derivatives and methods of use thereof
WO2014002922A1 (ja) 抗癌剤の併用による癌治療方法
HK1206253B (en) Combination of alisertib and paclitaxel for the treatment of cancer
TW201008944A (en) Therapeutic combination comprising an aurora kinase inhibitor and an antineoplastic agent
JP2015163591A (ja) 抗癌剤の併用による癌治療方法

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG TJ TM RU